Co-Diagnostics, Inc. is trading 20.3% down at $6.80 as traders continue to unwind positions following last week’s extreme Ebola-driven surge and subsequent pullback.
- The stock has experienced high volatility after a rapid move from $2.39 on May 20 to intraday levels that represented a gain of over 600% on Ebola-related speculation.
- Today’s decline reflects ongoing profit-taking and price normalization as the market corrects from the recent speculative spike.